Table 7.

Recommended Evaluations Following Initial Diagnosis of RRM2B-MDMD Progressive External Ophthalmoplegia

System/ConcernEvaluationComment
Eyes Complete ophthalmologic exam
  • Assess best corrected visual acuity; nystagmus, saccades & smooth pursuit; vertical & horizontal gaze limitation; ptosis.
  • Consider need for corrective measures incl prisms &/or surgery
Neurologic Neurologist: assess for cerebellar motor dysfunction (gait & postural ataxia, dysmetria, dysdiadochokinesis, tremor, dysarthria, nystagmus, saccades & smooth pursuit).Use standardized scale to establish baseline for ataxia (SARA, ICARS, or BARS). 1
Assess for myopathy (weakness, sensory loss)
Speech For those w/dysarthria: speech/language evalConsider referral to speech & language pathologist.
Bulbar
dysfunction
For those w/frequent choking or severe dysphagia, assess:
  • Nutritional status;
  • Aspiration risk.
Consider involving a gastroenterology/nutrition/feeding team, incl formal swallowing eval.
Mobility/ADL Orthopedics / physical medicine & rehab / PT evalTo incl assessment of:
  • Muscle tone; joint range of motion; posture; mobility; strength, coordination & endurance; pain; bedsores
  • Need for adaptive devices
  • Footwear needs
  • PT needs
OTTo assess
  • Small motor function (e.g., hands, feet, face, fingers, toes)
  • ADL
Cognitive/
Psychiatric
Assess for cognitive dysfunction assoc w/cerebellar cognitive affective syndrome (executive function, language processing, visuospatial/visuoconstructional skills, emotion regulation)Consider use of:
  • CCAS Scale to evaluate cognitive & emotional involvement;
  • Psychiatrist, psychologist, neuropsychologist if needed.
Gastrointestinal
dysmotility
Gastroenterology follow up
  • Measure height & weight.
  • Calculate BMI.
  • Serial weight measurement
Sensorineural
hearing loss
Complete audiologic exam incl hearing test, BAEPConsider hearing aids, cochlear implant
Speech &
language
Eval by speech & language pathologist
Endocrinopathy Eval by endocrinologistFor diabetes mellitus, hypothyroidism, hypoparathyroidism, hypogonadism
Genetic Counseling By healthcare practitioner w/experience in both genetic counseling & mitochondrial diseaseTo inform affected persons & their family re nature, MOI, & implications of RRM2B-MDMD to facilitate medical & personal decision making
Family support
& resources
Assess need for:

ADL = activities of daily living; BAEP = brain stem auditory evoked potentials; BARS = Brief Ataxia Rating Scale; BMI = body mass index; CCAS = cerebellar cognitive affective syndrome; ICARS = International Co-operative Ataxia Rating Scale; MOI = mode of inheritance; OT = occupational therapy; PT = physical therapy; SARA = Scale for the Assessment and Rating of Ataxia

1.

From: RRM2B Mitochondrial DNA Maintenance Defects

Cover of GeneReviews®
GeneReviews® [Internet].
Adam MP, Feldman J, Mirzaa GM, et al., editors.
Seattle (WA): University of Washington, Seattle; 1993-2024.
Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.